Cagent Vascular
Summary active Updated Jun 1, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Cagent Vascular is a Pennsylvania-based medical device company developing the Serranator Serration Remodeling Therapy (SRT) platform and the Serranator SONIC Intravascular Lithotripsy (IVL) System, which transmits ultrasonic acoustic waves through a balloon and its serrated metal elements directly into calcified plaque to improve vessel compliance at low inflation pressures 12. On May 19, 2026, the company announced the closing of an oversubscribed $41M Series D financing and reported the first human use of the Serranator SONIC IVL System, performed in Uzbekistan as part of the REMODEL I prospective study 12. Proceeds will support completion of the pivotal REMODEL II trial and commercial activities surrounding SONIC IVL 12.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-05-19 | Series D | $41M | U.S. Venture Partners, Astoria Health Investors | — 12 |
What Investors Say
No independently sourced investor commentary beyond standard announcement copy.
What Founders Say
No independently sourced founder testimonials found at this time.
Sources
-
“Cagent Vascular Reports First Human Use of Serranator SONIC IVL System and Closes Oversubscribed $41M Series D Financing,” BusinessWire, May 19, 2026. Accessed May 2026. https://www.businesswire.com/news/home/20260519501876/en/Cagent-Vascular-Reports-First-Human-Use-of-Serranator-SONIC-IVL-System-and-Closes-Oversubscribed-$41M-Series-D-Financing↩↩↩↩
-
“Cagent Vascular reports first-in-human IVL cases, closes $41M Series D,” MassDevice, May 2026. Accessed May 2026. https://www.massdevice.com/cagent-vascular-first-human-ivl-cases/↩↩↩↩